Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.43 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308567 | 0.92 | MAPK14 (0.42) | GSK3BMAPK14PIK3CAPIP5K1CPIK3C3 | |
| SCHEMBL10288318 | 0.91 | PIK3C3 (0.46) | GSK3BAURKAGSK3AMAPK14PIK3CA | |
| SCHEMBL627288 | 0.91 | PIK3C3 (0.43) | GSK3BAURKAGSK3AMAPK14PIK3CA | |
| SCHEMBL626764 | 0.88 | MAPK14 (0.44) | GSK3BAURKAGSK3AMAPK14PIK3CA | |
| SCHEMBL953124 | 0.86 | MAPK14 (0.47) | MAPK14PIK3CAPIP5K1CPIK3C3MAPT | |
| SCHEMBL953912 | 0.81 | MAPK14 (0.42) | GSK3BMAPK14PIK3C3 | |
| SCHEMBL6842878 | 0.81 | MAPK14 (0.49) | GSK3BMAPK14PIK3CAPIP5K1CPIK3C3 | |
| SCHEMBL954822 | 0.80 | MAPK14 (0.45) | GSK3BMAPK14PIK3CAPIP5K1CPIK3C3 | |
| SCHEMBL10288547 | 0.80 | PIK3C3 (0.43) | GSK3BMAPK14PIK3CAPIP5K1CPIK3C3 | |
| SCHEMBL10288393 | 0.79 | ACHE (0.35) | GSK3BMAPK14MAPTGPR142ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175563-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | GSK3B 57/4885AURKA 1184/4885GSK3A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.